Compare · ANIP vs NVO
ANIP vs NVO
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANIP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $204.85B, about 113.2x ANIP ($1.81B).
- Over the past year, ANIP is up 25.6% and NVO is down 32.0% - ANIP leads by 57.6 points.
- ANIP has been more active in the news (7 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 11 for ANIP).
- Company
- ANI Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $82.90+2.92%
- $47.40+3.29%
- Market cap
- $1.81B
- $204.85B
- 1M return
- +0.27%
- +6.83%
- 1Y return
- +25.63%
- -32.01%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 7
- 3
- Recent ratings
- 11
- 25
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANIP
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $41,015 worth of shares (500 units at $82.03) as part of a pre-agreed trading plan, decreasing direct ownership by 0.64% to 77,890 units (SEC Form 4)
- Director Thoma Jeanne was granted 4,357 shares, increasing direct ownership by 19% to 27,762 units (SEC Form 4)
- Director Tannenbaum Renee P was granted 4,357 shares, increasing direct ownership by 17% to 29,514 units (SEC Form 4)
- Director Pera Antonio R was granted 4,357 shares, increasing direct ownership by 19% to 27,017 units (SEC Form 4)
- Director Leonard Matthew J was granted 4,357 shares, increasing direct ownership by 63% to 11,221 units (SEC Form 4)
- Director Haughey Thomas was granted 4,357 shares and sold $161,760 worth of shares (2,000 units at $80.88) as part of a pre-agreed trading plan, increasing direct ownership by 6% to 38,878 units (SEC Form 4)
- SVP & CFO Carey Stephen P. exercised 3,312 shares at a strike of $49.51 and sold $264,960 worth of shares (3,312 units at $80.00) as part of a pre-agreed trading plan (SEC Form 4)
- ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Walsh Patrick D sold $1,127,120 worth of shares (13,973 units at $80.66), decreasing direct ownership by 27% to 38,432 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S